Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Current Leases (2022 - 2025)

Terns Pharmaceuticals filings provide 4 years of Current Leases readings, the most recent being $474000.0 for Q4 2025.

  • Quarterly Current Leases rose 10.75% to $474000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $474000.0 through Dec 2025, up 10.75% year-over-year, with the annual reading at $474000.0 for FY2025, 10.75% up from the prior year.
  • Current Leases hit $474000.0 in Q4 2025 for Terns Pharmaceuticals, up from $459000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $707000.0 in Q3 2023 and bottomed at $249000.0 in Q2 2024.
  • Average Current Leases over 4 years is $518562.5, with a median of $529000.0 recorded in 2022.
  • The largest annual shift saw Current Leases crashed 61.87% in 2024 before it skyrocketed 78.31% in 2025.
  • Terns Pharmaceuticals' Current Leases stood at $661000.0 in 2022, then dropped by 8.77% to $603000.0 in 2023, then decreased by 29.02% to $428000.0 in 2024, then rose by 10.75% to $474000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Current Leases are $474000.0 (Q4 2025), $459000.0 (Q3 2025), and $444000.0 (Q2 2025).